Results 151 to 160 of about 6,154,847 (249)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Serum 25-Hydroxyvitamin D Levels in Breast Cancer Patients: A Cross-Sectional Analysis by Molecular Tumor Subtypes. [PDF]

open access: yesJ Clin Med
Weber D   +7 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

D. N. Wadia: a Biographical Sketch

open access: yesJournal of the Palaeontological Society of India, 1957

doaj   +1 more source

D. Seifried, N. Stark: Energiedienstleistungen - Rezension

open access: yesTechnikfolgenabschätzung – Theorie und Praxis, 1994
Torsten Fleischer
doaj   +1 more source

Home - About - Disclaimer - Privacy